Bellicum Pharmaceuticals, Inc.
Bellicum Announces Interim Results Showing Rimiducid Controlled GvHD in Patients Treated with Rivo-cel Following a Stem Cell Transplant
Experience to date in clinical study shows high clinical response rates for patients with visceral GvHD or GvHD that was refractory to standard of care treatment
December 1, 2018